Immunic director granted options for 25,370 shares

IMMUNIC, INC. director Richard Alan Rudick received a grant of stock options covering 25,370 shares of common stock as equity compensation.

Rhea-AI Filing Summary

IMMUNIC, INC. director Richard Alan Rudick received a grant of stock options covering 25,370 shares of common stock as equity compensation. The options have an exercise price of $14.80 per share, vest in monthly increments over one year from the grant date, and expire on July 5, 2036. Following this award, he directly holds 25,370 derivative securities.

Insider Trade Summary

Grant/Award: 25,370 shares

Grant/Award 1 txn

Insider Rudick Richard Alan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	25,370	$0.00	$0.00

Holdings After Transaction: Stock Option — 25,370 contracts (Direct)

Footnotes (1)

1. F1. The option vests in monthly increments over a period of one year from the grant date.

Key Figures

Stock options granted: 25,370 options Exercise price: $14.80 per share Expiration date: July 5, 2036 +1 more

4 metrics

Stock options granted 25,370 options Director Richard Alan Rudick equity award

Exercise price $14.80 per share Strike price for granted stock options

Expiration date July 5, 2036 Option term end for this grant

Post-grant derivative holdings 25,370 derivative securities Total options held directly after transaction

Key Terms

Stock Option, Grant, award, or other acquisition, exercise price, vesting

4 terms

Stock Option financial

"security_title: Stock Option"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 14.8000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The option vests in monthly increments over a period of one year"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Immunic (IMUX) report for Richard Alan Rudick?

Immunic reported that director Richard Alan Rudick received a grant of stock options for 25,370 shares of common stock. This equity award was reported on a Form 4 as a compensation-related acquisition, not as an open-market purchase or sale.

What are the key terms of Richard Rudick’s new Immunic (IMUX) stock options?

Richard Rudick’s options cover 25,370 shares of Immunic common stock at an exercise price of $14.80 per share. They expire on July 5, 2036 and were granted at no upfront cost as a compensation-related stock option award.

How do Richard Rudick’s Immunic (IMUX) stock options vest over time?

The stock options granted to Richard Rudick vest in monthly increments over one year from the grant date. This means portions of the 25,370-share award become exercisable each month until fully vested after the one-year period.

Is Richard Rudick’s Immunic (IMUX) Form 4 transaction a stock purchase or sale?

The Form 4 reflects a grant of stock options classified as an acquisition, not an open-market stock purchase or sale. The transaction code “A” indicates a grant, award, or other acquisition of derivative securities, with no sale reported in this filing.

How many Immunic (IMUX) derivative securities does Richard Rudick hold after this grant?

After the stock option grant, Richard Rudick directly holds 25,370 derivative securities linked to Immunic common stock. These represent options that may be exercised at $14.80 per share before the stated expiration date, subject to vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/07/2026 - 04:06 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rudick Richard Alan

(Last) (First) (Middle)

1200 AVENUE OF THE AMERICAS, SUITE 200

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IMMUNIC, INC. [ IMUX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$14.8	07/05/2026		A		25,370		(1)	07/05/2036	Common Stock	25,370	$0.00	25,370	D

Explanation of Responses:

1. The option vests in monthly increments over a period of one year from the grant date.

	/s/ Richard A. Rudick	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)